Simple Summary Multiple Myeloma (MM) is a hematologic malignancy caused by aberrant
plasma cell proliferation in the bone marrow (BM) and constitutes the second most common …

The approval of the first two monoclonal antibodies targeting CD38 (daratumumab) and
SLAMF7 (elotuzumab) in late 2015 for treating relapsed and refractory multiple myeloma …

Multiple myeloma (MM), a bone marrow–resident hematological malignancy of plasma cells,
has remained largely incurable despite dramatic improvements in patient outcomes in the …

Immunotherapy will significantly impact the standard of care in cancer treatment. Recent
advances in nanotechnology can improve the efficacy of cancer immunotherapy. However …

The progression of multiple myeloma, a hematologic malignancy characterized by
unregulated plasma cell growth, is associated with increasing innate and adaptive immune …

Multiple myeloma (MM) is a plasma cell malignancy and the second most common
hematological neoplasm in adults, comprising 1.8% of all cancers. With an annual incidence …

The treatment paradigm in myeloma is constantly changing. Upfront use of monoclonal
antibodies like daratumumab along with proteasome inhibitors (PI) s, and immune …

Multiple myeloma (MM) is a clonal plasma cell malignancy affecting a predominantly elderly
population. The continued development of newer therapies with novel mechanisms of action …

Immunotherapy is emerging as a groundbreaking cancer treatment, offering the
unprecedented opportunity to effectively treat and in several cases, even cure previously …

Multiple myeloma (MM), a terminally differentiated B-cell malignancy, is characterized by
excess bone marrow (BM) plasma cells and immunosuppression. At present, the role of B …